Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 5/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272846 | 0.82 | DDR1 (0.55) | DDR1KIT | |
| SCHEMBL29614753 | 0.81 | KIT (0.65) | KITSRCABL1BRAFEGFR | |
| SCHEMBL20227773 | 0.81 | KIT (0.65) | KITSRCABL1BRAFEGFR | |
| SCHEMBL3557511 | 0.79 | DDR1 (0.56) | DDR1KITBRAF | |
| SCHEMBL30486141 | 0.78 | KIT (0.47) | DDR1KITSRCABL1BRAF | |
| SCHEMBL272847 | 0.78 | NR1H2 (0.63) | DDR1 | |
| SCHEMBL30486106 | 0.78 | KIT (0.44) | KITSRCABL1BRAFNTRK1 | |
| SCHEMBL19072901 | 0.78 | DDR1 (0.51) | DDR1KIT | |
| SCHEMBL30900112 | 0.77 | CYP2C9 (0.52) | KITSRCABL1BRAFKDR | |
| Hydrochloric Acid SCHEMBL3555518 | 0.77 | DDR1 (0.57) | DDR1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2022226182-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | DDR1 3149/4885KIT 4277/4885SRC 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.